Welch Allyn, a leading global manufacturer of frontline medical products and solutions, today announced it has added Masimo® continuous and noninvasive total hemoglobin (SpHb®) to its Connex® Vital Signs Monitor (CVSM). Made possible through a strategic partnership with Masimo Corporation (NASDAQ: MASI), the availability of SpHb on the CVSM multiparameter device enables healthcare professionals to obtain rapid and continuous hemoglobin measurements at the point-of-care without drawing blood. Instead, Masimo’s SpHb parameter—part of the Masimo rainbow® SET Pulse CO-Oximetry™ platform—uses advanced signal processing of multiple wavelengths of light obtained from noninvasive, easy-to-apply finger sensors.
“The addition of Masimo SpHb to our CVSM gives healthcare professionals in acute care settings complete and real-time visibility of one of their patients’ critical vital signs without waiting for lab results,” said Kelley Murphy, global category director at Welch Allyn. “It allows clinicians to monitor hemoglobin levels minute-by-minute—providing an early warning sign of possible bleeding, enabling timely intervention to improve patient safety and avoid potentially unnecessary cost and risks associated with blood transfusions.”
The Masimo SpHb parameter can be purchased in all CVSM devices equipped with the Masimo rainbow SET platform either at time of initial monitor purchase or at a later date via a simple software upgrade completed over the internet using Welch Allyn’s innovative PartnerConnect™ Remote Services solution. This same remote software upgradeability will be available for other rainbow SET parameters as Welch Allyn makes them available in the future.
In addition to SpHb the CVSM captures other automatic measurements such as heart rate, blood pressure, temperature and pulse oximetry (SpO2); manual parameters such as respiration, height, weight and pain level; and modifiers such as body position, O2 therapy details and others.
When used as part of the Welch Allyn Connex® Electronic Vitals Documentation (EVD) System, the device can wirelessly transfer patient data to an electronic medical record (EMR). Medical charting and documentation errors are reduced thereby improving clinical decision-making and patient outcomes.
According to a study published by the journal Infection Control & Hospital Epidemiology, bleeding significantly increases the length of stay and cost of care. The availability of a total hemoglobin monitoring solution on a system that captures and wirelessly transmits patient data to an EMR significantly minimizes these issues.
Masimo President of Worldwide OEM Business & Corporate Development, Rick Fishel, stated, “Masimo SpHb adds a critical noninvasive monitoring component and a new dimension of care for clinicians using the CVSM. Prior to SpHb, measuring hemoglobin was an invasive, time-consuming, and intermittent process that often resulted in delayed detection and intervention of occult bleeding. The integration of SpHb and the upgradeability of the rainbow SET platform in such a portable, cost-effective, easy-to-use multiparameter device with advanced EMR connectivity makes the CVSM a powerful and unique multiparameter monitoring solution.”
Welch Allyn Connex® Vitals Management (VM) Software is the backbone of the system, which automates the vitals documentation process to eliminate manual steps and the errors that go with them. With Connex VM software integrated into an EMR system, users can document accurate patient data, including total hemoglobin, right from the bedside—giving clinicians instant access to patient data anytime, anywhere and allowing them to identify abnormal vital signs more quickly.
The CVSM gives the clinician the ability to control alarms, patient data and monitoring in a customized manner for each patient, and they can document this data right on the device via a full-color, touchscreen interface—eliminating the need to locate a PC and transcribe it later. The monitor also enables two-way wireless communication from the bedside. It associates ID numbers to names to help clinicians properly identify patients and allows them to customize which ID fields are required and how they’re displayed, including simultaneous display of multiple forms of ID. The wireless technology is built right into the system, allowing the monitor to act as a true mobile device, and it works with current wireless networks to deliver up-to-date patient demographics.
To ensure satisfaction, the CVSM is backed by Welch Allyn Partners in Care ServicesSM, a support service that assists the facility with complete installation and integration, operation support, software updates and many other service features. The service offers training to get facility staff up to speed and can also certify biomedical technicians online to enable them to perform system repairs and maintain equipment in-house.
About Welch Allyn
Founded in 1915 and headquartered in Skaneateles Falls, NY (USA), Welch Allyn is a leading global provider of medical diagnostic equipment and a complete range of digital and connected solutions. With 2,750 employees working in 26 different countries, Welch Allyn is a family-owned business that specializes in helping doctors, nurses, and other frontline practitioners across the globe provide the best patient care by developing innovative products, breakthrough technologies, and cutting-edge solutions that help them see more patients, detect more conditions, and improve more lives. More information about Welch Allyn and its complete line of connected products and solutions may be found at www.welchallyn.com.
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow® SET Pulse CO-OximetryTM technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOCTM), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow Acoustic MonitoringTM, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo’s rainbow SET technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices. Masimo SET and Masimo rainbow SET technologies can be also found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care … by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.